Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 1191

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 1191
---
 other person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties and assets to any person, then, and in each such case, proper provision shall be made so that the successors and assigns of Cara or the Surviving Corporation, as the case may be, shall succeed to the indemnification obligations set forth in the Merger Agreement. Cara shall cause the Surviving Corporation to perform all of the director and officer indemnification obligations of the Surviving Corporation under the Merger Agreement.**

<div align='center'>II-2</div>

TABLE OF CONTENTS

Item 21 — Exhibits and Financial Statement Schedules (a) The following exhibits are filed herewith or incorporated herein by reference:

| ​             | ​ | ​ | ​                                                                                                                                                                            | ​ | ​ | Incorporated by Reference |   |   |            |   |   |        | ​ | ​ | ​             | ​ | ​ | ​                      | ​ | ​ | ​               | ​ |
| ExhibitNumber | ​ | ​ | Exhibit Description                                                                                                                                                          | ​ | ​ | Form                      | ​ | ​ | Date       | ​ | ​ | Number | ​ | ​ | FiledHerewith | ​ | ​ | To beFiled byAmendment | ​ | ​ | PreviouslyFiled | ​ |
| 2.1†          | ​ | ​ | Agreement and Plan of Merger and Reorganization, dated December 17, 2024, by and among Cara Therapeutics, Inc., CT Convergence Merger Sub, Inc. and Tvardi Therapeutics, In. | ​ | ​ | 8-K                       | ​ | ​ | 12/18/2024 | ​ | ​ |    2.1 | ​ | ​ | ​             | ​ | ​ | ​                      | ​ | ​ | ​               | ​ |
| 2.2†          | ​ | ​ | Asset Purchase Agreement, dated December 17, 2024, by and among Cara Therapeutics, Inc., Cara Royalty Sub, LLC and Vifor Fresenius Medical Care Renal Pharma, Ltd.           | ​ | ​ | 8-K                       | ​ | ​ | 12/18/2024 | ​ | ​ |   10.4 | ​ | ​ | ​             | ​ | ​ | ​                      | ​ | ​ | ​               | ​ |
| 3.1           | ​ | ​ | Amended and